Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1252)	7/18/2005 2:59:23 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

PPHM Is going over its July Hs.<g> They increased their research expenses in relation to Tarvacin, for which they received clearance from the FDA to initiate two clinical trials for the treatment of solid cancers and hepatitis C virus. They also increased expenses in relation to Cotara, for which they plan to initiate ae PII/III for the treatment of brain Ca. Revenues at Avid Bioservices,their wholly-owned subsidiary, increased $1.645M (a 54% increase) to $4.684M The insiders did some buying in May,June & July as the stock dipped below the $1 level.<g> Today the stock is up 12% and volume is over 4.9M The stock seems ready to test its June 22 H at 1.19 <g> bigcharts.marketwatch.com Bernard